Sumitomo Mitsui Trust Group
RXRX icon

Sumitomo Mitsui Trust Group’s Recursion Pharmaceuticals RXRX Stock Holding History

Sumitomo Mitsui Trust Group’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$16.6M Sell
5,419,221
-801,804
-13% -$3.1M 0.01% 637
2025
Q4 		$25.4M Sell
6,221,025
-1,244,833
-17% -$6.17M 0.01% 604
2025
Q3 		$36.4M Sell
7,465,858
-701,887
-9% -$3.69M 0.02% 553
2025
Q2 		$41.3M Sell
8,167,745
-311,539
-4% -$1.53M 0.03% 507
2025
Q1 		$44.9M Sell
8,479,284
-501,317
-6% -$3.65M 0.03% 469
2024
Q4 		$60.7M Sell
8,980,601
-786,127
-8% -$5.29M 0.04% 399
2024
Q3 		$64.4M Sell
9,766,728
-220,302
-2% -$1.58M 0.04% 388
2024
Q2 		$74.9M Sell
9,987,030
-375,773
-4% -$3.28M 0.06% 332
2024
Q1 		$103M Buy
10,362,803
+1,159,023
+13% +$12.9M 0.07% 286
2023
Q4 		$90.7M Buy
9,203,780
+5,680,656
+161% +$40.5M 0.07% 314
2023
Q3 		$27M Buy
3,523,124
+2,685,724
+321% +$26.8M 0.02% 623
2023
Q2 		$6.26M Buy
837,400
+335,423
+67% +$2.35M ﹤0.01% 820
2023
Q1 		$3.35M Buy
501,977
+47,455
+10% +$376K ﹤0.01% 866
2022
Q4 		$3.5M Sell
454,522
-36,218
-7% -$355K ﹤0.01% 877
2022
Q3 		$5.22M Buy
490,740
+90,839
+23% +$920K ﹤0.01% 842
2022
Q2 		$3.25M Buy
+399,901
New +$2.68M ﹤0.01% 904
2022
Q1 		– Sell
-368,994
Closed -$6.32M – 1230
2021
Q4 		$6.32M Sell
368,994
-40,200
-10% -$756K ﹤0.01% 817
2021
Q3 		$9.42M Buy
409,194
+195,586
+92% +$5.54M 0.01% 781
2021
Q2 		$7.8M Buy
+213,608
New +$6.32M ﹤0.01% 816

Other funds holding RXRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Sumitomo Mitsui Trust Group's RXRX Position: Q1 2026 in Review

Sumitomo Mitsui Trust Group reduced its Recursion Pharmaceuticals (RXRX) stake by 13% in Q1 2026, selling an estimated $3.1M and leaving 5,419,221 shares worth $16.6M. The position accounts for 0.01% of the portfolio, ranked #637.

Sumitomo Mitsui Trust Group first reported a position in RXRX in Q2 2021 and has held it in 19 quarters since. The position peaked at $103M in Q1 2024. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

  • Sumitomo Mitsui Trust Group held 5,419,221 shares of Recursion Pharmaceuticals worth $16.6M as of Q1 2026.
  • Sumitomo Mitsui Trust Group sold 801,804 Recursion Pharmaceuticals shares in Q1 2026, an estimated $3.1M.
  • Recursion Pharmaceuticals made up 0.01% of Sumitomo Mitsui Trust Group's portfolio in Q1 2026, its #637 holding.
  • Sumitomo Mitsui Trust Group first reported a position in Recursion Pharmaceuticals in Q2 2021 and has held it in 19 quarters since.
  • Sumitomo Mitsui Trust Group's Recursion Pharmaceuticals position peaked at $103M in Q1 2024.
  • 334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Sumitomo Mitsui Trust Group's 13F filing for Q1 2026, filed 30 Apr 2026.